Stepping-Stones Towards Triple Agonism: A Summary of GLP-1/GIP and GLP-1/GCG Dual-Agonist Development The development of triple agonists for obesity has built upon successes of several dual combinations of entero-pancreatic hormone receptor agonists, in particular, GLP-1/GIP dual agonists and GLP-1/GCG dual agonists
Retatrutides 24% diarrhea rate delivers 24.2% average weight loss
Alcohol can affect glycemic control and interact with diabetes medications
Avoid Irritants Limit consumption of alcohol, caffeine, spicy foods, and acidic beverages, as these can increase stomach acid and irritation, especially on an empty stomach
Further, batch-specific analytical testing, including mass spectrometry, is performed in partnership with independent analytical labs to verify identity, composition, and consistency across production lots